![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2009 by the Genetics Society of America Drosophila convoluted/dALS Is an Essential Gene Required for Tracheal Tube Morphogenesis and Apical Matrix Organization *Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, Evanston, Illinois 60208 and †Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario M5S 3G5, Canada 1Present address: Laval University Cancer Research Center, CRCHUQ-Hôtel-Dieu de Québec, Québec, QC G1R 2J6, Canada. 2Corresponding author: Hogan Hall, Room 2-100, Northwestern University, Evanston, IL 60208. E-mail: beitel/at/northwestern.edu Communicating editor: T. Schüpbach Received December 9, 2008; Accepted January 20, 2009. Abstract Insulin-like growth factors (IGFs) control cell and organism growth through evolutionarily conserved signaling pathways. The mammalian acid-labile subunit (ALS) is a secreted protein that complexes with IGFs to modulate their activity. Recent work has shown that a Drosophila homolog of ALS, dALS, can also complex with and modulate the activity of a Drosophila IGF. Here we report the first mutations in the gene encoding dALS. Unexpectedly, we find that these mutations are allelic to a previously described mutation in convoluted (conv), a gene required for epithelial morphogenesis. In conv mutants, the tubes of the Drosophila tracheal system become abnormally elongated without altering tracheal cell number. conv null mutations cause larval lethality, but do not disrupt several processes required for tracheal tube size control, including septate junction formation, deposition of a lumenal/apical extracellular matrix, and lumenal secretion of Vermiform and Serpentine, two putative matrix-modifying proteins. Clearance of lumenal matrix and subcellular localization of clathrin also appear normal in conv mutants. However, we show that Conv/dALS is required for the dynamic organization of the transient lumenal matrix and normal structure of the cuticle that lines the tracheal lumen. These and other data suggest that the Conv/dALS-dependent tube size control mechanism is distinct from other known processes involved in tracheal tube size regulation. Moreover, we present evidence indicating that Conv/dALS has a novel, IGF-signaling independent function in tracheal morphogenesis. INSULIN and insulin-like growth factors (IGFs) control energy homeostasis and growth through evolutionarily conserved signaling pathways (reviewed by Pavelic et al. 2007). Key regulators of these pathways are IGF binding proteins (IGFBPs) that modulate IGF activity, transport, and stability. The mammalian acid-labile subunit (ALS) forms ternary complexes with IGFs and IGFBP-3 or IGFBP-5 (reviewed by Boisclair et al. 2001). It has recently been shown that a Drosophila homolog of ALS, dALS, forms a ternary complex with Drosophila insulin-like peptide-2 (Dilp2) and the binding protein IMP-L2 (Arquier et al. 2008). Surprisingly, we find that the gene encoding dALS is allelic to convoluted (conv), a gene previously shown to be required for regulating the length of epithelial tubes in the Drosophila tracheal system (Beitel and Krasnow 2000). The Drosophila tracheal system is a ramifying network of epithelial tubes that delivers oxygen directly to target tissues (reviewed by Kerman et al. 2006). The tracheal system is among the best characterized systems for investigating branching morphogenesis and for control of epithelial tube size, an essential feature of many vital organs such as lung and kidney. The dimensions of tracheal tubes are regulated by at least two distinct mechanisms, one of which involves a transient lumenal extracellular matrix (ECM) (Tonning et al. 2005) and the putative matrix-modifying proteins Vermiform (Verm) and Serpentine (Serp) (Luschnig et al. 2006; Wang et al. 2006). Importantly, lumenal secretion of Verm requires the septate junction (SJ), which restricts paracellular diffusion similar to the vertebrate tight junction, but is located in the basolateral membrane and contains polarity proteins that promote basal membrane identity (Wu and Beitel 2004; reviewed in Swanson and Beitel 2006). Mutations that disrupt the matrix or Verm secretion cause individual tracheal cells, and thus the overall tubes, to become too long (Araujo et al. 2005; Moussian et al. 2005, 2006; Luschnig et al. 2006; Tonning et al. 2006; Wang et al. 2006). It has not been established whether the ECM provides a signal to the epithelial cells that causes them to adjust their dimensions or whether the ECM serves as a mandrel that shapes the tubes by physical forces. However, in addition to the matrix-based size control mechanism, there is evidence that growth factor signaling constitutes a second mechanism that controls tracheal tube size because mutation of chico, which encodes the Drosophila homolog of the mammalian insulin receptor substrates 1–4, shortens tracheal tube length to match the reduced body size of the chico mutant larva (Beitel and Krasnow 2000). Our analysis of the conv/dALS locus reveals that Conv activity defines a new step in the matrix-based size control process. Further, although Conv/dALS could potentially act through the insulin growth factor pathway to regulate tube size, our results suggest that the tracheal matrix organization function of Conv/dALS represents a distinct function from the IGF pathway function. MATERIALS AND METHODS Fly strains and genetics: Fly strains were obtained from the Bloomington or Szeged stock centers except for convR278, convY58, and the ppl-Gal4 and cg-Gal4 fat body drivers. convR278 was created by EMS mutagenesis of al1 dpov1 b1 pr1 c1 px1 sp1 followed by backcrossing to remove the markers. The convR278 genomic sequence is CACCATCGATGTCTTGCACAATAACATCTCC (C → T change is underlined). convY58 was created by mobilization of transposable element insertion SelDSH1599. The primers 5′-GCCTAGTAGTCCGAATCCAGTA and 5′-TGGCCCATATAGACGAACTAG were used to identify convY58, which templates a 103-bp band, while the wild-type (WT) chromosome produces a 2.3-kb band. The sequence across the convY58 deletion endpoints is 5′-CCAGTAATATCGGTATGCCCAT. Fat body drivers ppl-Gal4 and cg-Gal4 were a gift from P. Léopold. Molecular biology: RNAi was performed as previously described (Kennerdell and Carthew 1998), using primers 5′-AAACGGGAAATTCTTTTTTCAG and 5′-AATTTTATATTAGCAATTGTAC for CG8561. A 6-kb fragment for CG8561 genomic rescue construct was amplified from pBACe3.6 (BACPAC resources), using primers 5′-CTGGATCCGAGCGAGATGTCACAACAGGGTTGTATTA and 5′-ATGCGGCCGCTGAATGCTGATTTATGCCATTCGCCAC, and cloned into pCasper5 (Le et al. 2007). The genomic rescue construct with the convR278 mutation was created by Quickchange (Stratagene, La Jolla, CA) of the WT construct and subcloning into pUASTattB (Bischof et al. 2007). The WT conv cDNA was amplified by RT–PCR from OregonR RNA, using primers 5′-GCGAACTTGGTTTTGGGCCATGGGATAA and 5′-TCTTGGTGCACAGTTTTCCCATGC, and cloned into pBluescriptC5 (Le et al. 2007) and then into pUASTattB. The 3.3-kb fragment was moved into the SacII site of the pAC5-YFP plasmid in frame with the C-terminal YFP tag and the tagged construct was cloned into the pUASTattB vector. Transgenic flies were made either using P transposase (Rubin and Spradling 1982; Spradling and Rubin 1982) or the C31 integration systems (Bischof et al. 2007). The complete sequence of all constructs was determined using BigDye sequencing (Applied Biosystems, Foster City, CA). The accession number for conv cDNA is EU814872.Immunohistochemistry and imaging: Embryos were fixed and stained as previously described (Samakovlis et al. 1996). For clathrin stains, embryos were fixed in 4% paraformaldehyde and devitellinized in 80% ethanol to avoid the use of methanol. For assessment of lumenal clearance, WT and convR278 mutant embryos were collected in 1-hr lots and aged at 24°. Stage 16 embryos were predominantly found in the lot aged for 15 hr after collection, stage early 17 embryos were in the 16-hr lot, and stage mid-17 embryos were in the 17-hr lot. Primary antibodies used were anti-lumenal 2A12 1:5 (DSHB), anti-Coracle 1:500 (Fehon et al. 1994), anti-GFP 1:1000 (Abcam), rat anti-DE-cadherin DECAD2 1:20 (Oda et al. 1994), anti-Verm and Serp 1:300 (Luschnig et al. 2006), FITC-conjugated anti-Chitin binding probe 1:500 (New England Biolabs, Beverly, MA), and anti-clathrin 1:100 (Sigma, St. Louis). Secondary antibodies were used at 1:200 (Jackson Laboratories; Molecular Probes, Eugene, OR). To assess protein levels, heterozygous and homozygous embryos were imaged on the same slide in the same session. Electron micrograph (EM) images were obtained as in Wu et al. (2004). Paracellular barrier function was assessed using a 10-kDa dextran dye as described in Paul et al. (2003). None of nine convY58/Df(2R)7131 embryos showed dye leakage. Sequence analysis and biochemistry: Sequence alignment was done using ClustalW (Figure 2 Gal4 UAS-Conv-YFP 0- to 20-hr embryos or Escherichia coli expressing GFP homogenized in lysis buffer (Genova and Fehon 2003) and probed with rabbit polyclonal anti-GFP (Abcam) at 1:10,000. WT is OregonR.
RESULTS AND DISCUSSION CG8561 encodes convoluted: Although the original convK6507b allele was isolated from a screen of transposon-induced mutations, it is not associated with a transposable element (Beitel and Krasnow 2000). To obtain additional alleles, we performed a noncomplementation screen and isolated convR278, which fails to complement convK6507b and causes the same overly long tracheal phenotype as convK6507b (Figure 1D
To clone conv, we used recombination mapping and deficiency complementation to define a region of ~20 genes containing both convK6507b and convR278 (Figure 1I Convoluted is a leucine-rich repeat protein with similarity to mammalian ALS and Drosophila adhesion and signaling proteins: conv has very low embryonic expression levels, and no conv cDNAs were present in the publicly available cDNA libraries. We therefore used RT–PCR to assemble a complete cDNA and to confirm the predicted gene structure. The full-length cDNA is 3.3 kb long and has an open reading frame (ORF) of 1092 amino acids (aa) preceded by in-frame stop codons (Figure 1I The Conv protein has a strongly predicted signal sequence at the N terminus and multiple leucine-rich repeats (LRR) that are commonly involved in protein–protein interactions. A BLASTP search revealed that the closest human homolog of Conv is ALS of the insulin growth factor binding complex (Boisclair et al. 2001). In strong support of Conv having functional as well as sequence similarity to human ALS, recent work by Arquier et al. (2008) has demonstrated that Conv/dALS can bind and antagonize Dilp2 and that altering Conv/dALS levels can affect metabolism. As we have previously shown that larval tracheal length is reduced in chico mutants, which have reduced insulin-like growth factor signaling (Beitel and Krasnow 2000), the increased length of trachea in conv mutants is consistent with conv functioning to regulate tracheal tube length through insulin-like peptide signaling. Furthermore, the R278 mutation is located in a region of significant similarity between ALS and Conv/dALS and could potentially disrupt Conv/dALS insulin binding functions (Figure 1K Alternatively, although ALS is the closest human homolog of Conv/dALS, there are substantial differences between the two proteins that have not previously been noted (Figure 1J convoluted is an essential gene: Because Conv/dALS might be a multifunctional protein and it was unclear whether convK6507b and convR278 were null alleles, we created a conv null allele with which to definitively characterize Conv/dALS functions. Imprecise excision of the P-element SelDSH1599 created the small deficiency Df(2R)convY58 that deletes the entire intergenic region 5′ of conv as well as the first exon and a half of conv that include the transcriptional start site (Figure 1I Embryonic morphogenesis appears normal in both convR278 and convY58, with the notable exception of tracheal tube size-control defects (see below). Conv/dALS function is largely or entirely dispensable for neural and muscle function as larvae homozygous for convR278 or convY58 hatch and begin crawling. However, neither these homozygous larvae nor larvae trans-heterozygous for convR278/convY58 survive past the second larval stage, which is presumably due to the 100% penetrant failure of conv mutant trachea to fill with air and thereby provide oxygen to target tissues (Figure 3, B and D
Convoluted is required for tracheal tube-size control, but not for SJ assembly, chitin matrix deposition, or chitin deacetylase secretion: The trachea of embryos homozygous or trans-heterozyogous for conv mutations becomes abnormally long during stage 16 (Figure 1D To understand the role of Conv/dALS in tracheal tube-size control, we asked if conv mutations affect known mechanisms of tube-size control (reviewed in Swanson and Beitel 2006). Localization of apical polarity and SJ markers appears normal in conv null mutants, as is the ultrastructure of intercellular septa that form paracellular diffusion barriers (Figures 3, G and H
Convoluted is required for tracheal lumenal and apical extracellular matrix organization: The defect common to most currently identified mutations affecting tracheal tube-size control is that they disrupt organization of the tracheal apical and/or lumenal extracellular matrix (reviewed in Swanson and Beitel 2006). In conv mutants, EMs show that at stage 16, the lumenal matrix appears to be less dense and somewhat grainier than in WT (Figure 3, I and J In addition to lumenal matrix defects, conv mutants have grossly abnormal morphogenesis of the apical matrix (cuticle) that lines the tracheal surface. In conv mutants, the taenidia, which normally are stereotyped periodic ridges in the highly organized apical matrix, are frequently misshapen and flattened (Figure 3, I–L Convoluted defines a new step in the matrix-based tracheal tube-size control process: As mutations in genes encoding SJ proteins and conv both cause lumenal matrix defects, we performed additional genetic tests to determine whether there were differences between the effects of conv and SJ mutations on the extracellular matrix. We examined the genetic interactions of varicose (vari), which encodes an adaptor protein critical for SJ formation (Wu et al. 2007), and of conv with piopio (pio) and dumpy (dp). Pio and Dp are extracellular matrix proteins deposited in the tracheal lumen that contain ZP domains (Wilkin et al. 2000; Jazwinska et al. 2003; Bokel et al. 2005). ZP domains are named after proteins that form the zona pelucida, a gel-like substance surrounding mammalian oocytes (Jovine et al. 2005). Intriguingly, ZP domains can polymerize to form strands (Jovine et al. 2002), which in the trachea could potentially play a role parallel to that of the chitin-based fibrillar matrix. Alternatively, Pio and Dp are transmembrane proteins and thus could act as mediators of chitin-fibril-based signaling or scaffolding. Pio and Dp are required for the cell intercalation that produces unicellular tracheal branches (Jazwinska et al. 2003; Ribeiro et al. 2004). In strong pio and dp mutants intercalation fails to stop and unicellular tracheal branches become disconnected (Figure 5, F and N
In contrast to the enhancement of the vari length defects by dp and pio, double-mutant combinations of a strong conv allele and dp or pio did not have increased tracheal length (Figure 5, O and P Mutations in conv cause tracheal tube-length and matrix defects similar to those caused by mutations in the wurst locus, which encodes a J-domain transmembrane protein that is required for clathrin-mediated endocytosis of lumenal material (Behr et al. 2007). However, in contrast to wurst mutants, lumenal clearance of the 2A12 marker (Figure 4, I–N Expression of Convoluted in the trachea but not the fat body rescues epithelial morphogenesis defects: If Conv/dALS functions as a matrix-organizing or cell-adhesion protein, one would expect it to be localized to the tracheal apical cell surface or lumen. Unfortunately, our attempts to raise antibodies to Conv/dALS protein have been unsuccessful. We therefore attempted to determine the subcellular localization of Conv/dALS by expressing a YFP-tagged protein in the tracheal system using the ubiquitous da-Gal4 that efficiently expresses and rescues many tracheal genes (Wodarz et al. 1995; Wu et al. 2004, 2007; Paul et al. 2007). When expressed with da-Gal4, Conv YFP showed little accumulation in the tracheal system and its subcellular localization could not be reliably determined in tracheal cells by YFP fluorescence or by anti-YFP immunofluorescent staining (data not shown). Interestingly, although little Conv YFP was evident in the trachea, da-Gal4 driving Conv YFP almost completely rescued embryonic tracheal morphological defects (90%, n = 20; no rescue of adult viability, n > 100), suggesting either that very little Conv/dALS is required in the embryonic tracheal system or that Conv/dALS does not act in the embryonic tracheal system.To more directly address whether Conv/dALS acts in the tracheal system, we expressed Conv/dALS and Conv YFP using the btl-Gal4 driver that expresses only in the tracheal system and in some glia in the central nervous system (Shiga et al. 1996). With this driver, Conv YFP localized to the tracheal cytoplasm, suggesting that it was inefficiently trafficked to the cell surface (Figure 6B dALS construct expressed in the fat body and in cultured S2 cells. For the Conv YFP fusion, the cytoplasmic localization was not an artifact of cleavage of the C-terminal YFP tag as Western blots showed that almost all detectable GFP immunoreactivity was in a high molecular weight band that corresponds to the correct size of the Conv YFP fusion protein (Figure 6C
Despite poor trafficking of Conv YFP in the tracheal system, both tagged- and untagged-expression constructs fairly efficiently rescued embryonic tracheal defects in conv mutants (66%, n = 18, and 80%, n = 25, respectively; Figure 6, B and EConcluding remarks: Drosophila Conv/dALS has been characterized as an important player in the IGF signaling pathway where it forms a ternary complex containing Imp-L2 (Arquier et al. 2008). Here we report the first characterization of mutations in the gene encoding Drosophila ALS and find that in contrast to Imp-L2, conv/dALS is an essential gene. Surprisingly, Conv/dALS has an important role in tracheal epithelial morphogenesis, where it limits tube elongation. Although these results raise the fascinating possibility that Conv/dALS could act by dampening IGF signaling to prevent abnormal tracheal growth, the observations that Imp-L2 is not required for tracheal morphogenesis and that Conv/dALS appears to act autonomously in the tracheal system suggest that Conv/dALS has a tracheal-matrix organizing function that is distinct from its IGF-binding function. The exact role of Conv/dALS in matrix organization is unclear, but the apparently low level of embryonic Conv expression suggests that Conv/dALS acts as an important regulator rather than a structural component of the lumenal extracellular matrix. Acknowledgments We thank S. Paul for performing paracellular diffusion assays; V. Wu for DE-cadherin confocal microscopy; R. Carroll and H. Hong for technical assistance; K. Basler, R. Fehon, E. Hafen, S. Luschnig, M. Krasnow and P. Léopold for reagents; and I. T. Helenius and T. Krupinski for comments on the manuscript. This work was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR) (to P.L.) and a predoctoral fellowship from the National Institutes of Health (NIH) Cell and Molecular Basis of Disease training grant (T32 GM008061 to K.S.N.). Operating support was provided by the CIHR (to U.T.) and the NIH (R01 GM069540 to G.J.B.). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Indian J Med Res. 2007 Apr; 125(4):511-22.
[Indian J Med Res. 2007]J Endocrinol. 2001 Jul; 170(1):63-70.
[J Endocrinol. 2001]Cell Metab. 2008 Apr; 7(4):333-8.
[Cell Metab. 2008]Development. 2000 Aug; 127(15):3271-82.
[Development. 2000]Differentiation. 2006 Sep; 74(7):326-48.
[Differentiation. 2006]Dev Cell. 2005 Sep; 9(3):423-30.
[Dev Cell. 2005]Curr Biol. 2006 Jan 24; 16(2):186-94.
[Curr Biol. 2006]Curr Biol. 2006 Jan 24; 16(2):180-5.
[Curr Biol. 2006]Curr Opin Cell Biol. 2004 Oct; 16(5):493-9.
[Curr Opin Cell Biol. 2004]Cell. 1998 Dec 23; 95(7):1017-26.
[Cell. 1998]Proc Natl Acad Sci U S A. 2007 Feb 27; 104(9):3312-7.
[Proc Natl Acad Sci U S A. 2007]Science. 1982 Oct 22; 218(4570):348-53.
[Science. 1982]Science. 1982 Oct 22; 218(4570):341-7.
[Science. 1982]Development. 1996 May; 122(5):1395-407.
[Development. 1996]Development. 1994 Mar; 120(3):545-57.
[Development. 1994]Dev Biol. 1994 Oct; 165(2):716-26.
[Dev Biol. 1994]Curr Biol. 2006 Jan 24; 16(2):186-94.
[Curr Biol. 2006]J Cell Biol. 2004 Jan 19; 164(2):313-23.
[J Cell Biol. 2004]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D142-4.
[Nucleic Acids Res. 2004]J Cell Biol. 2003 Jun 9; 161(5):979-89.
[J Cell Biol. 2003]Development. 2000 Aug; 127(15):3271-82.
[Development. 2000]J Endocrinol. 2001 Jul; 170(1):63-70.
[J Endocrinol. 2001]Cell Metab. 2008 Apr; 7(4):333-8.
[Cell Metab. 2008]Development. 2000 Aug; 127(15):3271-82.
[Development. 2000]Cell. 1988 Jan 29; 52(2):291-301.
[Cell. 1988]EMBO J. 1990 Jun; 9(6):1969-77.
[EMBO J. 1990]Proc Natl Acad Sci U S A. 2000 Sep 12; 97(19):10520-5.
[Proc Natl Acad Sci U S A. 2000]Dev Biol. 2007 Jul 1; 307(1):53-61.
[Dev Biol. 2007]Cell. 1999 Jun 25; 97(7):865-75.
[Cell. 1999]J Biol. 2008; 7(3):10.
[J Biol. 2008]Curr Biol. 2006 Jan 24; 16(2):R51-3.
[Curr Biol. 2006]Curr Biol. 2006 Jan 24; 16(2):R51-3.
[Curr Biol. 2006]Cell. 1999 Jun 25; 97(7):865-75.
[Cell. 1999]J Biol. 2008; 7(3):10.
[J Biol. 2008]Development. 2000 Aug; 127(15):3271-82.
[Development. 2000]Development. 2007 Mar; 134(5):999-1009.
[Development. 2007]Curr Biol. 2000 May 18; 10(10):559-67.
[Curr Biol. 2000]Nat Cell Biol. 2003 Oct; 5(10):895-901.
[Nat Cell Biol. 2003]J Cell Sci. 2005 Feb 1; 118(Pt 3):633-42.
[J Cell Sci. 2005]Annu Rev Biochem. 2005; 74():83-114.
[Annu Rev Biochem. 2005]Nat Cell Biol. 2007 Jul; 9(7):847-53.
[Nat Cell Biol. 2007]Cell. 1995 Jul 14; 82(1):67-76.
[Cell. 1995]J Cell Biol. 2004 Jan 19; 164(2):313-23.
[J Cell Biol. 2004]Development. 2007 Mar; 134(5):999-1009.
[Development. 2007]Development. 2007 Jan; 134(1):147-55.
[Development. 2007]Cell Metab. 2008 Apr; 7(4):333-8.
[Cell Metab. 2008]J Biol. 2008; 7(3):10.
[J Biol. 2008]Cell. 2003 Sep 19; 114(6):739-49.
[Cell. 2003]Cell Metab. 2008 Apr; 7(4):333-8.
[Cell Metab. 2008]J Cell Biol. 2006 Jun 19; 173(6):963-74.
[J Cell Biol. 2006]Cell Metab. 2008 Apr; 7(4):333-8.
[Cell Metab. 2008]